Preferred Label : Cytokine Release Syndrome;
NCIt definition : A syndrome that occurs after therapeutic infusion of antibodies into the blood and
is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness
of breath. It is caused by the release of cytokines from the cells that are targeted
by the antibodies. Most patients experience a mild to moderate reaction; however,
the reaction may be severe and life-threatening.;
Alternative definition : CTCAE: A disorder characterized by nausea, headache, tachycardia, hypotension, rash,
and shortness of breath; it is caused by the release of cytokines from the cells.; NICHD: A systemic inflammatory reaction caused by the release of an excessive amount
of cytokines into the circulation by activated T-cells.;
Codes from synonyms : E11264;
Origin ID : C78251;
UMLS CUI : C0948245;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
Manual BTNT mappings - CISMeF
Semantic type(s)
UMLS correspondences (same concept)
concept_is_in_subset
https://ansm.sante.fr/tableau-marr/glofitamab
2025
false
false
false
France
French
guidelines for drug use
risk management
antibodies, bispecific
antibodies, bispecific
glofitamab
glofitamab
patients guideline
Tumor Flare Reaction
signs and symptoms
continuity of patient care
Cytokine Release Syndrome
glofitamab
---
https://presse.inserm.fr/plusieurs-formes-dorages-cytokiniques-sont-associes-a-la-severite-et-la-mortalite-dans-la-covid-19/42738
2021
false
false
false
France
French
scientific and technical information
cytokine storm syndrome
Cytokine Release Syndrome
cytotoxicity, immunologic
cytokines
case management
cytokine storm syndrome in COVID-19
pneumonia, viral
coronavirus infections
pandemics
pneumonia, viral
coronavirus infections
pandemics
pneumonia, viral
coronavirus infections
pandemics
pneumonia, viral
coronavirus infections
pandemics
coronavirus infections
COVID-19
COVID-19
COVID-19
COVID-19
---